被Biotech老戏骨秀了一脸

瞪羚社
07 Jan

短短过了几个月,天境杭州与赛诺菲的BD就掀起了波澜。2024年九月,天境杭州以大约2.5亿人民币的首付款拿到了CD73单抗的尤莱利单抗(Uliledlimab)的大中华区开发及商业化权益,且该药的后续临床推进主要是由天境杭州负责。而昨晚海外的天境生物(I-MAB)却传来消息,公司宣布放弃CD73单抗的开发,转而将重点放在推进CLDN18.2/4-1BB双抗Givastomig(TJ-CD4B)的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10